Isis Pharmaceuticals other research news
ISIP published animal data in the Journal of Pharmacology and Experimental Therapeutics showing that medicinal chemistry can be used to modify antisense compounds to improve their therapeutic profiles. The study looked at the effect of various chemical modifications on pharmacokinetic, pharmacological and toxicological properties of the compounds. These properties included the binding affinity of the modified antisense compounds for their target mRNAs, their ability to reduce mRNA levels and inhibit protein production, and their ability to reduce side effects.
The study used a first generation phosphorothioate oligonucleotide, ISIS 3082, and five analogs. ISIS 3082 is a mouse analog of ISIS 2302, an inhibitor of human intercellular adhesion molecule-1 ( ICAM-1), which is in Phase II trials in five inflammatory conditions. ...